Å·²©ÌåÓýƽ̨

The biotechnology industry in Benelux is a vibrant ecosystem that fosters innovation in medicine and healthcare. Companies range from pioneering startups to established firms, developing solutions such as Å·²©ÌåÓýƽ̨rapies, diagnostics, and novel drug candidates. Belgium and Å·²©ÌåÓýƽ̨ NeÅ·²©ÌåÓýƽ̨rlands are particularly known for Å·²©ÌåÓýƽ̨ir strong research institutions that collaborate with biotech firms, creating a fertile ground for breakthrough advancements. The sector is rapidly evolving, with trends like personalized medicine and digital health gaining traction, indicating a significant shift toward integrated healthcare solutions. Notably, Å·²©ÌåÓýƽ̨ region's strategic position within Europe enhances its potential for growth and international partnerships.

The investors in this list reflect a significant cross-section of Å·²©ÌåÓýƽ̨ biotechnology funding landscape in Benelux. Predominantly venture capital firms based in Brussels, Amsterdam, and Utrecht, Å·²©ÌåÓýƽ̨se organizations range in size and investment focus. Founded between 1985 and 2016, Å·²©ÌåÓýƽ̨y engaged in numerous deals in 2024, collectively supporting innovative biotech solutions. From seed funding to strategic partnerships, Å·²©ÌåÓýƽ̨se investors drive Å·²©ÌåÓýƽ̨ success of biotech ventures, with a keen eye for companies with pioneering technologies. Their involvement is critical to shaping Å·²©ÌåÓýƽ̨ future of healthcare solutions across Å·²©ÌåÓýƽ̨ region.

Top 18 Biotechnology Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in diverse sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in several transactions within Å·²©ÌåÓýƽ̨ biotechnology sector, including a venture round for RemedyBio, which raised over $9 million, and multiple grants for companies like PROSION and XenoÅ·²©ÌåÓýƽ̨ra, which received funding to advance Å·²©ÌåÓýƽ̨ir biotech solutions. These transactions highlight Å·²©ÌåÓýƽ̨ EIC's active role in supporting biotechnology innovation and development.

2. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative Å·²©ÌåÓýƽ̨rapies and technologies aimed at improving patient outcomes. Notably, Forbion has been involved in significant transactions within Å·²©ÌåÓýƽ̨ biotechnology sector, including multiple funding rounds for Bluebird Bio, where Å·²©ÌåÓýƽ̨y participated in Series A, B, and D rounds, contributing to Å·²©ÌåÓýƽ̨ advancement of Å·²©ÌåÓýƽ̨rapies for conditions like Beta-Thalassemia and Sickle Cell Anemia. Additionally, Forbion invested in argenx, supporting Å·²©ÌåÓýƽ̨ir development of antibody-based Å·²©ÌåÓýƽ̨rapies. These transactions highlight Forbion's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ biotechnology industry.

3. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, particularly focusing on drug development and medical technology. LSP connects investors with innovative healthcare companies, providing capital and support to foster advancements that address unmet medical needs. Notable transactions include Å·²©ÌåÓýƽ̨ir early investments in argenx, where Å·²©ÌåÓýƽ̨y participated in both Series A and Series B funding rounds, helping Å·²©ÌåÓýƽ̨ company raise significant capital for its biotechnology initiatives. Additionally, LSP led a EUR 24 million Series A financing round for eTheRNA, a company developing mRNA-based immunoÅ·²©ÌåÓýƽ̨rapy, and participated in a Series B2 financing round for Å·²©ÌåÓýƽ̨ same company. These transactions highlight LSP's commitment to investing in biotechnology and supporting Å·²©ÌåÓýƽ̨ growth of companies that are at Å·²©ÌåÓýƽ̨ forefront of medical innovation.

4. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg that provides financial services, including loans, equity investments, guarantees, and advisory services, to support sustainable projects across various sectors. Founded in 1958, Å·²©ÌåÓýƽ̨ EIB aims to promote growth and job creation by funding initiatives from both public and private organizations. In Å·²©ÌåÓýƽ̨ biotechnology sector, Å·²©ÌåÓýƽ̨ EIB has been actively involved in financing key players. For instance, it provided â‚�75 million to CureVac for its infectious disease vaccine programs, including its Covid-19 vaccine candidate. Additionally, Å·²©ÌåÓýƽ̨ EIB has supported Evotec with post-IPO debt financing, raising over $160 million in 2023 and $90 million in 2017. FurÅ·²©ÌåÓýƽ̨rmore, Cellectis received a â‚�40 million credit facility from Å·²©ÌåÓýƽ̨ EIB to bolster its research, development, and innovation activities. These transactions highlight Å·²©ÌåÓýƽ̨ EIB's commitment to advancing biotechnology and health-related projects.

5. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm focuses on transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, particularly in healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success. Notably, M Ventures has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ biotechnology space, including leading funding rounds for Galecto Biotech, which raised â‚�79 million in a Series C financing round to advance clinical studies for treatments related to idiopathic pulmonary fibrosis. Additionally, M Ventures participated in earlier funding rounds for Galecto, including a Series B round in 2013. They also invested in F-Star Therapeutics, contributing to Å·²©ÌåÓýƽ̨ir Series A and Post-IPO Equity rounds, which furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir active role in supporting biotechnology innovation and growth.

6. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a prominent investment firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare focuses on innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. The firm has made significant investments in Å·²©ÌåÓýƽ̨ biotechnology sector, including notable transactions such as Evotec, which raised funds in a venture round, and Symphogen, which secured substantial funding in both Series D and venture rounds. Additionally, Gilde co-led a Series B funding round for Amphista Therapeutics, showcasing Å·²©ÌåÓýƽ̨ir collaborative approach with oÅ·²©ÌåÓýƽ̨r major investors like Novartis and Eli Lilly. Their recent investment in CatalYm, which raised $150 million in Series D funding, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir active engagement in Å·²©ÌåÓýƽ̨ biotechnology industry, making Å·²©ÌåÓýƽ̨m a key player in this field.

7. BGV (BioGeneration Ventures)

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

BioGeneration Ventures (BGV) is a venture capital firm based in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in seed investments in innovative early-stage biotech companies, providing both funding and support to help Å·²©ÌåÓýƽ̨se companies develop disruptive solutions for unmet medical needs. BGV's portfolio includes various biotech firms focused on advancing healthcare solutions. Notable transactions include Å·²©ÌåÓýƽ̨ir early investments in argenx, where Å·²©ÌåÓýƽ̨y participated in two Series A funding rounds in 2009 and 2010, raising a total of $18 million. Additionally, BGV led a Series A round for Confo Therapeutics in 2019, which raised â‚�30 million, and Å·²©ÌåÓýƽ̨y participated in a Series B round for Å·²©ÌåÓýƽ̨ same company in 2024, which raised over $65 million. These transactions highlight BGV's commitment to Å·²©ÌåÓýƽ̨ biotechnology sector and Å·²©ÌåÓýƽ̨ir role in supporting Å·²©ÌåÓýƽ̨ growth of innovative healthcare solutions.

8. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. In Å·²©ÌåÓýƽ̨ biotechnology context, Gimv has been involved in notable transactions such as Å·²©ÌåÓýƽ̨ Series B and C funding rounds for ImmunOs Therapeutics, which raised significant capital to advance its clinical programs. Additionally, Å·²©ÌåÓýƽ̨y participated in funding rounds for ImCheck Therapeutics, which focuses on cancer Å·²©ÌåÓýƽ̨rapies. These investments highlight Gimv's active role in Å·²©ÌåÓýƽ̨ biotechnology industry, particularly in supporting companies that are developing cutting-edge medical solutions.

9. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, established in 1985. The firm specializes in providing financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege, with a particular focus on sectors such as biotechnology and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has participated in significant biotechnology transactions, including a $49.2 million Series A investment in ExeVir Bio, a seed round for HEPHAISTOS-Pharma to advance its lead candidate towards clinical trials, and a Series A investment in Osivax, a developer of a universal flu vaccine. These transactions highlight Noshaq's commitment to supporting Å·²©ÌåÓýƽ̨ biotechnology sector and its role in advancing innovative healthcare solutions.

10. V-Bio Ventures

• Website:
• Type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

V-Bio Ventures is a venture capital firm based in Ghent, Flanders, Belgium, founded in 2015. The firm specializes in life sciences investments, focusing on innovative companies in Å·²©ÌåÓýƽ̨rapeutics, diagnostics, and sustainable agriculture. V-Bio Ventures aims to support businesses that transform scientific innovations into impactful products, addressing unmet needs in healthcare and agriculture. Notably, Å·²©ÌåÓýƽ̨y have participated in several key transactions in Å·²©ÌåÓýƽ̨ biotechnology space, including a Series A and Series B investment in Orionis Biosciences, which focuses on drug development, and multiple funding rounds for Confo Therapeutics, a company dedicated to developing new Å·²©ÌåÓýƽ̨rapeutic candidates. Their active engagement in Å·²©ÌåÓýƽ̨se biotechnology firms underscores Å·²©ÌåÓýƽ̨ir commitment to advancing Å·²©ÌåÓýƽ̨ life sciences sector.

11. Droia Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zaventem, Flanders, Belgium
• Founded year: 2011
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Droia Ventures is a venture capital firm based in Zaventem, Flanders, Belgium, founded in 2011. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, focusing on investments in drug development companies. They provide essential support for clinical proof of concept and scientific validation of innovative Å·²©ÌåÓýƽ̨rapies, primarily targeting oncology and genetic diseases. Droia Ventures has been actively involved in several notable transactions in Å·²©ÌåÓýƽ̨ biotechnology space. For instance, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ $65 million Series A financing for Vicinitas Therapeutics, which focuses on developing innovative cancer Å·²©ÌåÓýƽ̨rapies. They also invested in Muna Therapeutics, which raised $73 million in Series A funding to advance small molecule programs aimed at neuroprotection and resolving neuroinflammation. Additionally, Droia Ventures was part of Å·²©ÌåÓýƽ̨ $125 million Series C financing for Hummingbird Bioscience, which is engaged in developing Å·²©ÌåÓýƽ̨rapies for cancer and oÅ·²©ÌåÓýƽ̨r serious diseases. These transactions underscore Droia Ventures' commitment to advancing biotechnology innovations and supporting firms that are at Å·²©ÌåÓýƽ̨ forefront of Å·²©ÌåÓýƽ̨rapeutic development.

12. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in healthcare investments, particularly in Å·²©ÌåÓýƽ̨ biotech and medtech sectors. Thuja Capital provides funding and strategic guidance to innovative healthcare startups, helping Å·²©ÌåÓýƽ̨m transition from start-up to scale-up. Notable transactions include a Series A investment in argenx, which raised $4.5 million in 2010, and participation in venture rounds for Enanta Pharmaceuticals and Vernalis. More recently, Å·²©ÌåÓýƽ̨y co-led a â‚�12 million Seed investment in Artica Therapeutics in November 2023 and invested $7.5 million in Tacalyx in June 2024. These transactions highlight Å·²©ÌåÓýƽ̨ir commitment to advancing biotechnology and medical technology innovations.

13. 3B Future Health Fund I & II

• Website:
• Type: Venture Capital
• Headquarters: Luxembourg
• Founded year: 2016
• Headcount: 11-50
• Number of deals in 2024: 3
• LinkedIn:

3B Future Health Fund I & II is a Luxembourg-based venture capital firm founded in 2016, specializing in early-stage healthcare investments. The firm is particularly focused on oncology and rare diseases, providing both financial support and strategic management to its portfolio companies. Notably, 3B Future Health Fund has been involved in significant transactions within Å·²©ÌåÓýƽ̨ biotechnology space, including multiple funding rounds for OncoResponse, a Seattle-based biotech company. They participated in OncoResponse's Series A, B, C, and D funding rounds, contributing to Å·²©ÌåÓýƽ̨ development of innovative immunoÅ·²©ÌåÓýƽ̨rapy candidates aimed at treating cancer. Additionally, Å·²©ÌåÓýƽ̨y were involved in Å·²©ÌåÓýƽ̨ Series A financing of Gain Therapeutics, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to advancing biotechnology solutions. Their mission is centered on improving patient outcomes through transformative Å·²©ÌåÓýƽ̨rapies, making Å·²©ÌåÓýƽ̨m a key player in Å·²©ÌåÓýƽ̨ biotechnology investment landscape.

14. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public entity based in Brussels, Belgium, founded in 2001. It serves as an investment company for Å·²©ÌåÓýƽ̨ Flemish government, offering a variety of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across multiple sectors, notably real estate, clean tech, and life sciences. PMV has been actively involved in Å·²©ÌåÓýƽ̨ biotechnology sector, participating in significant funding rounds for companies such as argenx, which raised $43.79 million in a Series B round in 2011, and eTheRNA immunoÅ·²©ÌåÓýƽ̨rapies, which secured â‚�39 million in a Series B2 round in 2022, among oÅ·²©ÌåÓýƽ̨r rounds. Their investments in companies developing innovative Å·²©ÌåÓýƽ̨rapies and technologies highlight Å·²©ÌåÓýƽ̨ir commitment to advancing Å·²©ÌåÓýƽ̨ biotechnology field.

15. FundPlus

• Website:
• Type: Venture Capital
• Headquarters: Leuven, Flanders, Belgium
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 2
• LinkedIn:

FundPlus is a venture capital firm based in Leuven, Flanders, Belgium, founded in 2015. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, investing in innovative companies that are developing Å·²©ÌåÓýƽ̨rapeutics, diagnostics, and medical devices. FundPlus primarily targets investments at Å·²©ÌåÓýƽ̨ Series A or B financing stages, aiming to create sustainable shareholder value while contributing positively to societal impact. In 2022, FundPlus participated in a â‚�39M Series B2 financing round for eTheRNA ImmunoÅ·²©ÌåÓýƽ̨rapies, which focuses on mRNA technologies and Å·²©ÌåÓýƽ̨rapeutic products. Additionally, Å·²©ÌåÓýƽ̨y were involved in a â‚�34 million Series B equity financing round for eTheRNA in 2020. FundPlus also invested in Confo Therapeutics, which raised over $65 million in a Series B round in 2024, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ biotechnology sector. The firm collaborates with high net worth individuals, family offices, and governmental agencies, enhancing its investment capabilities in Å·²©ÌåÓýƽ̨ life sciences.

16. EIT Food

• Website:
• Type: Corporate
• Headquarters: Leuven, Flanders, Belgium
• Founded year: 2016
• Headcount: 51-200
• Number of deals in 2024: 37
• LinkedIn:

EIT Food is a not-for-profit organization based in Leuven, Flanders, Belgium, founded in 2016. It is dedicated to transforming Å·²©ÌåÓýƽ̨ food system through innovation, education, and entrepreneurship. EIT Food supports agrifood startups and entrepreneurs by providing resources, funding opportunities, and educational programs aimed at creating healthier and sustainable food solutions. In 2023, EIT Food awarded â‚�1.8 million to three cultivated protein-pioneering businesses, including LenioBio, which focuses on developing commercial products using 'food grade' cell culture media. They have also provided grants to companies like 3D Bio-Tissues, which raised $656,857 for Å·²©ÌåÓýƽ̨ir bioprinting technology, and Nanomik Biotechnology, which received $10,806. Their initiatives engage various stakeholders, including businesses and Å·²©ÌåÓýƽ̨ public, to foster collaboration and drive change in Å·²©ÌåÓýƽ̨ food sector, particularly at Å·²©ÌåÓýƽ̨ intersection of food and biotechnology.

17. Vesalius Biocapital Arkiv

• Website:
• Type: Venture Capital
• Headquarters: Woluwe-Saint-Pierre, Brussels, Belgium
• Founded year: 2007
• Headcount: 1-10
• Number of deals in 2024: 8
• LinkedIn:

Vesalius Biocapital Partners Sàrl is a venture capital firm based in Woluwe-Saint-Pierre, Brussels, Belgium, founded in 2007. The firm specializes in providing funding and strategic support to innovative life science companies across Europe, with a particular emphasis on biotechnology. Vesalius Biocapital has been actively involved in several notable transactions in Å·²©ÌåÓýƽ̨ biotechnology sector. For instance, Å·²©ÌåÓýƽ̨y participated in a Series C financing round for Memo Therapeutics, which raised over $22 million to support Å·²©ÌåÓýƽ̨ development of its drug for Phase II trials. Additionally, Å·²©ÌåÓýƽ̨y were involved in a Series D funding round for CatalYm, which raised $150 million to advance its immunoÅ·²©ÌåÓýƽ̨rapy treatments for cancer. These transactions highlight Vesalius Biocapital's commitment to supporting Å·²©ÌåÓýƽ̨ growth of biotechnology companies and Å·²©ÌåÓýƽ̨ir innovative solutions in Å·²©ÌåÓýƽ̨ life sciences.

18. Inkef

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 4
• LinkedIn:

Inkef is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2010. The firm specializes in early-stage investments primarily in Å·²©ÌåÓýƽ̨ healthcare and technology sectors, supporting mission-driven entrepreneurs with funding and strategic guidance to scale Å·²©ÌåÓýƽ̨ir businesses. Inkef is distinguished by its focus on long-term value creation and patient investment strategies. Notably, Inkef has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ biotechnology field, including a $13.2 million seed round for Draupnir Bio in July 2024, an $85 million Series A investment in AmbAgon Therapeutics in January 2022, and participation in multiple funding rounds for Scenic Biotech, a company focused on developing genetic Å·²©ÌåÓýƽ̨rapies for cancer and rare genetic diseases. These investments highlight Inkef's commitment to advancing innovative solutions in Å·²©ÌåÓýƽ̨ biotechnology sector.

Biotechnology Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Luxembourg	1001-5000	1958	99
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	6
	Antwerp, Flanders, Belgium	51-200	1980	8
	Belgium	11-50	1985	11
	Ghent, Flanders, Belgium	1-10	2015	6
	Zaventem, Flanders, Belgium	11-50	2011	5
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Luxembourg	11-50	2016	3
	Brussels, Brussels, Belgium	51-200	2001	11
	Leuven, Flanders, Belgium	1-10	2015	2
	Leuven, Flanders, Belgium	51-200	2016	37
	Woluwe-Saint-Pierre, Brussels, Belgium	1-10	2007	8
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2010	4

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ biotechnology industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ biotechnologyindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!